摘要
目的分析托伐普坦联合依那普利治疗心力衰竭的效果及对血清炎性因子、sST2、PRA、sICAM-1水平的影响。方法选择本院2018年3月至2019年3月收治的150例心力衰竭患者为研究对象,按电脑数字表法将其随机分为对照组与试验组,各75例。对照组予以依那普利治疗,试验组予以托伐普坦联合依那普利治疗。比较两组患者的治疗效果。结果试验组的治疗总有效率显著高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组患者的血清TNF-α、CRP、IL-6、sST2、PRA及sICAM-1水平均显著降低,且试验组显著低于对照组,差异均具有统计学意义(P<0.05)。结论托伐普坦联合依那普利治疗心力衰竭的效果显著,可降低患者血清TNF-α、CRP、IL-6、sST2、PRA及sICAM-1水平,值得临床推广。
Objective To analyze the effect of tolvaptan combined with enalapril in the treatment of heart failure and its influence on the levels of serum inflammatory factors,sST2,PRA and sICAM-1.Methods A total of 150 patients with heart failure admitted in our hospital from March 2018 to March 2019 were selected as the study objects.The patients were randomly divided into control group and experimental group according to the method of computer digital table,with 75 cases in each group.The control group was treated with enalapril,and the experimental group was treated with tolvaptan combined with enalapril.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the experimental group was significantly higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of TNF-α,CRP,IL-6,sST2,PRA and sICAM-1 in the two groups significantly decreased,and those in the experimental group were significantly lower than the control group,and the differences were statistically significant(P<0.05).Conclusion Tolvaptan combined with enalapril has a significant effect in the treatment of heart failure,it can reduce the serum levels of TNF-α,CRP,IL-6,sST2,PRA and sICAM-1 of patients,which is worthy of promotion in clinic.
作者
李军朋
王璇
LI Jun-peng;WANG Xuan(No.215 Hospital of Shaanxi Nuclear Industry,Xianyang 712000;Xianyang Hospital of Yan'an University,Xianyang 712000,China)
出处
《临床医学研究与实践》
2020年第18期37-39,共3页
Clinical Research and Practice
